Effects of human recombinant interleukin 2 on in vitro tumor cytotoxicity in dogs.
In these studies, the effects of recombinant human interleukin 2 (rHuIL-2) were examined on in vitro tumor cytotoxicity by canine blood lymphocytes obtained from peripheral vessels through use of a chromium release microcytotoxicity assay. Cytotoxic activity by lymphokine-activated killer cells was significantly increased, compared with that by untreated lymphocytes in a dose-dependent manner. The maximal effect was attained with 300,000 IU of rHuIL-2/ml. Lymphokine-activated killing also was dependent on the duration of incubation with rHuIL-2. After 1 day of rHuIL-2 incubation, cytotoxicity was significantly increased, compared with that of untreated lymphocytes. Of the 3 times examined, cytotoxicity peaked after 3 days of rHuIL-2 incubation. High levels of cytotoxic activity were still present at 7 days of incubation. Numbers of granular lymphocytes increased over the times examined. These results demonstrate functional and morphologic changes in canine peripheral blood lymphocytes obtained from peripheral vessels after incubation with rHuIL-2 in a dose- and time-dependent manner.
Raskin
R E
RE
Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610.
Holcomb
C S
CS
Maxwell
A K
AK
D000230:Adenocarcinoma / Q000276:immunology / Q000662:veterinary; D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004283:Dog Diseases / Q000276:immunology; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology* / Q000633:toxicity; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000633:toxicity; D013964:Thyroid Neoplasms / Q000276:immunology / Q000662:veterinary; D013997:Time Factors; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011994:Recombinant Proteins